Optimal Concentration of Remifentanil for NIM Tube Intubation with Low-dose NMBA

Last updated: March 15, 2025
Sponsor: Kyungpook National University Chilgok Hospital
Overall Status: Completed

Phase

N/A

Condition

Ear, Nose, And Throat (Ent) Surgeries

Treatment

Remifentanil

Clinical Study ID

NCT06162390
KNUCH 2023-10-033
  • Ages 20-60
  • Female
  • Accepts Healthy Volunteers

Study Summary

During thyroid surgery, Intraoperative Neuromonitoring (IONM) plays a crucial role in preventing serious complications such as bilateral vocal cord paralysis. It achieves this by detecting damage to the recurrent laryngeal nerve (RLN) and predicting the RLN's functional status. The utilization of Nerve Integrity Monitoring tubes (NIM tubes) is on the rise for effective IONM. As IONM relies on observing electromyographic (EMG) responses to direct electrical nerve stimulation, the routine use of neuromuscular blocking agents (NMBAs) in general anesthesia can impact the interpretation of IONM results and potentially reduce sensitivity to nerve responses to stimulation. However, the use of NMBAs is essential for ensuring smooth endotracheal intubation in patients undergoing general anesthesia. Numerous studies suggest that NMBA usage provides superior intubation conditions and reduces vocal cord complications compared to scenarios without NMBA.

Various regimens for neuromuscular blockade methods are employed during IONM in thyroid surgery, ranging from not using NMBAs at all to using a full dose of NMBA for intubation. This is followed by the administration of sugammadex, an NMBA reversal agent, before nerve monitoring. One of the methods known for providing satisfactory intubation conditions while ensuring the quality of EMG signals during IONM in thyroid surgery is using rocuronium at an ED95 dose of 0.3 mg/kg. This approach is considered suitable for most IONM scenarios. However, when adequate muscle relaxation is not achieved, not all patients can undergo intubation, necessitating a strategy for appropriate intubation conditions.

Historically, it has been reported that achieving satisfactory intubation conditions without the use of NMBA during general anesthesia requires higher amounts of propofol and opioids. Therefore, the assumption is made that using remifentanil, an opioid used in total intravenous anesthesia (TIVA), at an appropriate concentration can provide acceptable intubation conditions with minimal NMBA use for patients undergoing IONM.

This study aims to determine the optimal concentration of remifentanil needed to achieve excellent intubation conditions in patients undergoing thyroid surgery with IONM using rocuronium 0.3 mg/kg as the NMBA during TIVA

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All female aged 20-60

  • ASA (American Society of Anesthesiologists) physical status I or II

  • who scheduled for thyroidectomy under intraoperative neuromonitoring with a nerveintegrity monitoring tube (NIM tube)

Exclusion

Exclusion Criteria:

  • Patients anticipated to experience challenging intubation.

  • Patients who have had an upper respiratory tract infection within the past 2 weeks.

  • Patients with a history of heart, lung, and kidney diseases.

  • Patients with a body mass index (BMI) of 30 kg/m² or higher.

  • Patients currently taking analgesics.

  • Patients expressing a desire not to participate in the study.

Study Design

Total Participants: 21
Treatment Group(s): 1
Primary Treatment: Remifentanil
Phase:
Study Start date:
November 20, 2023
Estimated Completion Date:
March 20, 2024

Connect with a study center

  • Sung Hye Byun

    Daegu, 41404
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.